Clinical trial · Interventional
OM202JP Clinical Study of KNP2002
A Phase II Clinical Study of KNP2002 Ointment in Patients With Common Warts (OM202JA)
NCT05896215CI-TRIAL-00081134completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Common Wart | Verruca Vulgaris | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| KNP2002 | Drug | — | UNRESOLVED |
| Placebo of KNP2002 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Low dose group
- description
- Topical administration of low dose of KPN2002
- interventionNames
- Drug: KNP2002
- type
- EXPERIMENTAL
- label
- Middle dose group
- description
- Topical administration of middle dose of KPN2002
- interventionNames
- Drug: KNP2002
- type
- EXPERIMENTAL
- label
- High dose group
- description
- Topical administration of high dose of KPN2002
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 49 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects aged 15 to 49 years old * Subjects with common warts on the upper or lower limb * Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration * Subjects who have given their voluntary written consent to participate in this clinical trial Exclusion Criteria: * Subjects with 5 or more warts on the upper or lower limbs * Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts * Subjects with a history of allergy to topical skin preparations * Subjects with a history of malignant tumor within 5 years before administration of study drug * Subjects with any of the following diseases: Malignant tumor; Serious heart disease; Poorly controlled diabetes/hypertension * Women who are pregnant, may become pregnant, or are breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.